FACULTAD DE CIENCIAS BIOMÉDICAS Y DE LA SALUD
Facultad
GlaxoSmithKline (United Kingdom)
Londres, Reino UnidoPublicaciones en colaboración con investigadores/as de GlaxoSmithKline (United Kingdom) (10)
2023
-
Chronic Airways Assessment Test: psychometric properties in patients with asthma and/or COPD
Respiratory Research, Vol. 24, Núm. 1
2020
-
Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT
Therapeutic Advances in Respiratory Disease, Vol. 14
2018
-
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
The Lancet, Vol. 392, Núm. 10157, pp. 1519-1529
2014
2013
-
Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: Results from the randomised, placebo-controlled avodart after radical therapy for Prostate Cancer Study (ARTS)
European Urology, Vol. 63, Núm. 5, pp. 779-787
-
Reply from authors re: Behfar Ehdaie, Karim A. Touijer. 5-Alpha reductase inhibitors in prostate cancer: From clinical trials to clinical practice. Eur Urol 2013;63:788-9: 5-Alpha reductase inhibitors in prostate cancer
European Urology
2004
-
Cardiovascular effects of the nitric oxide synthase inhibitor N G-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002)
Critical Care Medicine, Vol. 32, Núm. 1, pp. 13-20
-
Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock
Critical Care Medicine, Vol. 32, Núm. 1, pp. 21-30
1999
-
Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: Results of a 1-year (1996-1997) multicenter surveillance study
Antimicrobial Agents and Chemotherapy, Vol. 43, Núm. 2, pp. 357-359
-
Multi-center, randomized, placebo-controlled, double blind study of the nitric oxide synthase inhibitor 546c88: Effect on survival in patients with septic shock
Critical Care Medicine, Vol. 27, Núm. 1 SUPPL.